ATE468853T1 - Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung - Google Patents
Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendungInfo
- Publication number
- ATE468853T1 ATE468853T1 AT05773502T AT05773502T ATE468853T1 AT E468853 T1 ATE468853 T1 AT E468853T1 AT 05773502 T AT05773502 T AT 05773502T AT 05773502 T AT05773502 T AT 05773502T AT E468853 T1 ATE468853 T1 AT E468853T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- methods
- compositions containing
- substituted pyrazoles
- pyrazoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59017204P | 2004-07-22 | 2004-07-22 | |
PCT/US2005/025541 WO2006014618A2 (en) | 2004-07-22 | 2005-07-19 | Substituted pyrazoles, compositions containing such compounds and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE468853T1 true ATE468853T1 (de) | 2010-06-15 |
Family
ID=35787673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05773502T ATE468853T1 (de) | 2004-07-22 | 2005-07-19 | Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung |
Country Status (9)
Country | Link |
---|---|
US (1) | US7625938B2 (de) |
EP (1) | EP1773330B1 (de) |
JP (1) | JP2008507528A (de) |
CN (1) | CN1993124A (de) |
AT (1) | ATE468853T1 (de) |
AU (1) | AU2005269792B9 (de) |
CA (1) | CA2574147A1 (de) |
DE (1) | DE602005021494D1 (de) |
WO (1) | WO2006014618A2 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE490244T1 (de) * | 2003-01-27 | 2010-12-15 | Merck Sharp & Dohme | Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren |
DK1756064T3 (da) * | 2004-06-04 | 2008-09-22 | Merck & Co Inc | Pyrazolderivater, sammensætninger indeholdende sådanne forbindelser og anvendelsesmetoder |
AU2006227435A1 (en) * | 2005-03-21 | 2006-09-28 | Merck Sharp & Dohme Corp. | Substituted aryl and heteroaryl derivatives |
TW200720254A (en) * | 2005-04-07 | 2007-06-01 | Nippon Kayaku Kk | Use of 3,5-diphenyl pyrazole derivatives as anti-tumor agent |
WO2008098244A1 (en) | 2007-02-09 | 2008-08-14 | Metabasis Therapeutics, Inc. | Novel antagonists of the glucagon receptor |
WO2009110520A1 (ja) * | 2008-03-05 | 2009-09-11 | 武田薬品工業株式会社 | 複素環化合物 |
US8623818B2 (en) | 2008-05-16 | 2014-01-07 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonists, compositions, and methods for their use |
PE20091972A1 (es) * | 2008-05-19 | 2010-01-15 | Schering Corp | Compuestos heterociclicos como inhibidores del factor ixa |
EP2314587A4 (de) * | 2008-07-17 | 2012-01-25 | Asahi Kasei Pharma Corp | Nitrogenierte heterocyclische verbindung |
CA2966273C (en) | 2008-08-13 | 2019-08-27 | Metabasis Therapeutics, Inc. | Glucagon antagonists |
ES2620027T3 (es) | 2008-09-03 | 2017-06-27 | Biomarin Pharmaceutical Inc. | Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC |
US8436015B2 (en) * | 2008-09-15 | 2013-05-07 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
EP2350020B1 (de) * | 2008-10-03 | 2014-08-13 | Merck Sharp & Dohme Corp. | Spiro-imidazolonderivate als glucagonrezeptorantagonisten |
WO2010093535A1 (en) | 2009-02-12 | 2010-08-19 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
WO2010098994A1 (en) | 2009-02-25 | 2010-09-02 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
EP2440553B1 (de) * | 2009-06-12 | 2017-08-23 | Merck Sharp & Dohme Corp. | Thiophene als glucagonrezeptorantagonisten, zusammensetzungen und verfahren zu ihrer verwendung |
US8735604B2 (en) | 2009-09-22 | 2014-05-27 | Merck Sharp & Dohme Corp. | Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use |
JP5568277B2 (ja) * | 2009-10-22 | 2014-08-06 | 株式会社日立ハイテクノロジーズ | パターンマッチング方法、及びパターンマッチング装置 |
NZ611529A (en) | 2010-12-23 | 2015-06-26 | Pfizer | Glucagon receptor modulators |
CN104744370A (zh) | 2011-02-08 | 2015-07-01 | 辉瑞大药厂 | 胰高血糖素受体调节剂 |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US9540395B2 (en) | 2011-02-28 | 2017-01-10 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
BR112014000288A2 (pt) | 2011-07-22 | 2017-01-10 | Pfizer | moduladores do receptor de glucagon de quinolinila |
TW201427658A (zh) | 2012-12-10 | 2014-07-16 | Merck Sharp & Dohme | 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法 |
DK2970139T3 (en) | 2013-03-15 | 2018-08-13 | Biomarin Pharm Inc | HDAC inhibitors |
EP3065736B1 (de) | 2013-11-04 | 2018-11-14 | Merck Sharp & Dohme Corp. | Glucagon-rezeptor-antagonist-verbindungen, zusammensetzungen daraus und verfahren zur verwendung |
US10076504B2 (en) | 2014-06-12 | 2018-09-18 | Ligand Pharmaceuticals, Inc. | Glucagon antagonists |
EP3506940A1 (de) | 2016-08-30 | 2019-07-10 | Regeneron Pharmaceuticals, Inc. | Verfahren zur behandlung schwerer insulinresistenz durch interferenz mit glucagonrezeptorsignalisierung |
EP3529278A1 (de) | 2016-10-20 | 2019-08-28 | Regeneron Pharmaceuticals, Inc. | Verfahren zur senkung des blutzuckerspiegels |
CA3071387A1 (en) | 2017-08-22 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating urea cycle disorders by interfering with glucagon receptor signaling |
US20210121422A1 (en) | 2018-02-13 | 2021-04-29 | Ligand Pharmaceuticals Incorporated | Glucagon receptor antagonists |
CN114276338B (zh) * | 2022-01-06 | 2023-11-28 | 苏州大学 | 2-吡唑-3-苯并咪唑衍生物及其制备方法和应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0859771A4 (de) | 1995-10-31 | 2000-03-15 | Merck & Co Inc | Substituierte pyridylpyrrole, solche verbindungen enthaltende zubereitungen und verfahren zu deren nutzung |
AR008789A1 (es) * | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
US5776954A (en) * | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
JP2000514088A (ja) | 1996-11-20 | 2000-10-24 | メルク エンド カンパニー インコーポレーテッド | グルカゴンアンタゴニストとしてのトリアリール置換イミダゾール |
WO1998022108A1 (en) | 1996-11-20 | 1998-05-28 | Merck & Co., Inc. | Triaryl substituted imidazoles and methods of use |
AU728760B2 (en) | 1996-11-20 | 2001-01-18 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
US6503949B1 (en) * | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
PL364750A1 (en) * | 1999-08-10 | 2004-12-13 | Nihon Bayer Agrochem K.K. | Herbicidal tetrazolinone derivatives |
US6562807B2 (en) * | 2000-06-23 | 2003-05-13 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
EP1305285B1 (de) | 2000-07-25 | 2007-05-16 | Merck & Co., Inc. | N-substituierte indole mit anwendung in der behandlung von diabetes |
US20030203946A1 (en) | 2000-11-17 | 2003-10-30 | Carsten Behrens | Glucagon antagonists/inverse agonists |
AU2002223501A1 (en) | 2000-11-17 | 2002-05-27 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
DE10122716A1 (de) * | 2001-05-10 | 2002-11-14 | Baeuerle Gmbh Mathias | Transporteinrichtung für flaches Transportgut, vorzugsweise Papier |
US6881746B2 (en) * | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
US6762318B2 (en) * | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
AU2002351730A1 (en) | 2001-12-19 | 2003-06-30 | Novo Nordisk A/S | Glucagon receptor antagonists/inverse agonists |
WO2003053938A1 (en) | 2001-12-20 | 2003-07-03 | Novo Nordisk A/S | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten |
WO2003064404A1 (fr) | 2002-02-01 | 2003-08-07 | Dainippon Pharmaceutical Co., Ltd. | Hydrazides d'acide 2-furancarboxylique et compositions pharmaceutiques les contenant |
EP1519723A1 (de) | 2002-06-27 | 2005-04-06 | Novo Nordisk A/S | Glucagon antagonisten/inverse agonisten |
DE60336724D1 (de) | 2002-07-19 | 2011-05-26 | Baxter Healthcare Sa | System für die peritonealdialyse |
WO2004050039A2 (en) | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Spirocyclic ureas, compositions containing such compounds and methods of use |
ATE490244T1 (de) * | 2003-01-27 | 2010-12-15 | Merck Sharp & Dohme | Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren |
WO2004092146A2 (en) | 2003-04-14 | 2004-10-28 | The Institutes For Pharmaceutical Discovery, Llc | N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes |
WO2004100875A2 (en) | 2003-05-09 | 2004-11-25 | Merck & Co., Inc. | Benzimidazoles, compositions containing such compounds and methods of use |
DK1756064T3 (da) | 2004-06-04 | 2008-09-22 | Merck & Co Inc | Pyrazolderivater, sammensætninger indeholdende sådanne forbindelser og anvendelsesmetoder |
AR056574A1 (es) | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
-
2005
- 2005-07-19 WO PCT/US2005/025541 patent/WO2006014618A2/en active Application Filing
- 2005-07-19 DE DE602005021494T patent/DE602005021494D1/de active Active
- 2005-07-19 JP JP2007522643A patent/JP2008507528A/ja not_active Withdrawn
- 2005-07-19 AU AU2005269792A patent/AU2005269792B9/en not_active Ceased
- 2005-07-19 CA CA002574147A patent/CA2574147A1/en not_active Abandoned
- 2005-07-19 US US11/632,198 patent/US7625938B2/en active Active
- 2005-07-19 CN CNA2005800246617A patent/CN1993124A/zh active Pending
- 2005-07-19 AT AT05773502T patent/ATE468853T1/de not_active IP Right Cessation
- 2005-07-19 EP EP05773502A patent/EP1773330B1/de not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
AU2005269792B2 (en) | 2008-07-03 |
EP1773330A2 (de) | 2007-04-18 |
US20080108620A1 (en) | 2008-05-08 |
DE602005021494D1 (de) | 2010-07-08 |
US7625938B2 (en) | 2009-12-01 |
WO2006014618A2 (en) | 2006-02-09 |
AU2005269792B9 (en) | 2008-11-27 |
EP1773330B1 (de) | 2010-05-26 |
EP1773330A4 (de) | 2009-01-21 |
CA2574147A1 (en) | 2006-02-09 |
CN1993124A (zh) | 2007-07-04 |
AU2005269792A1 (en) | 2006-02-09 |
WO2006014618A3 (en) | 2006-10-19 |
JP2008507528A (ja) | 2008-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE468853T1 (de) | Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung | |
EP1590336A4 (de) | Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren | |
WO2004100875A3 (en) | Benzimidazoles, compositions containing such compounds and methods of use | |
TW200745031A (en) | Acyl indoles, compositions containing such compounds and methods of use | |
TN2009000111A1 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
WO2007111864A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
WO2006104826A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
WO2004050039A3 (en) | Spirocyclic ureas, compositions containing such compounds and methods of use | |
MY143599A (en) | Pyrazole derivatives, compositions containing such compounds and methods of use | |
ATE435210T1 (de) | Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten | |
WO2005089118A3 (en) | Novel bicyclic compounds as modulators of androgen receptor function and method | |
ATE538650T1 (de) | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht | |
GEP20125565B (en) | Lactam compounds and their pharmaceutical use | |
DE60212801D1 (de) | Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie | |
ATE449604T1 (de) | Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren | |
NO20070487L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
TW200745044A (en) | Pyrazole derivatives, compositions containing such compounds and methods of use | |
DE602006020871D1 (de) | Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden | |
NO20076515L (no) | Hydantoinforbindelser | |
EA201170795A1 (ru) | Антагонисты ccr2 группы 4-азетидинил-1-гетероарил-циклогексанола | |
IL174762A0 (en) | Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker | |
WO2005060959A8 (en) | Pyrazole derivatives and use thereof as orexin receptor antagonists | |
EP1398029A8 (de) | 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden | |
ATE421519T1 (de) | Substituierte bizyklische thiophen-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren | |
WO2004024066A3 (en) | Method of treating diabetes and related conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |